| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 79, 542-546, Copyright © 1994 by Endocrine Society
ARTICLES |
AW Kung, CC Yau and A Cheng
Department of Medicine, University of Hong Kong.
Radioactive iodine-131 (RAI) has been reported to be associated with a high incidence of development or exacerbation of Graves' ophthalmopathy (GO). This is thought to be associated with a surge of autoantibodies after RAI therapy. The role of methimazole (MMI), which possesses immunomodulatory action, in the prevention of GO was explored by studying 114 patients with Graves' disease. They were assigned randomly to receive either RAI alone or adjunctive antithyroid drugs, which consisted of MMI and L-T4 as a block-replacement therapy for 12 months and were followed for 2 yr. Thirty-five patients (30.7%) had GO at presentation. Twenty-one (18%) patients developed new GO, and six had worsening of preexisting GO. The development of hypothyroidism (P < 0.01) and an elevation of TSH (P < 0.05) were associated with increased risk of development or exacerbation of GO. The chance of development or exacerbation of GO is higher in those with no ophthalmopathy than in those with preexisting GO at presentation (P = 0.002). The incidence of development or exacerbation of GO was similar in the two treatment groups (RAI, 22.8%; adjunctive antithyroid drugs, 23.7%; P = NS). MMI was able to suppress the surge of TSH receptor antibody (TRAB) after RAI, but a surge in TRAB was not of prognostic significance for the development of GO after RAI. Patients who developed or had exacerbation of GO actually had lower TRAB at presentation (P = 0.02). We conclude that hypothyroidism with elevated TSH is an important adverse factor for the development or exacerbation of GO, and MMI was unable to prevent the development or exacerbation of GO after RAI.
This article has been cited by other articles:
 |
|
 |
|
  F. Traisk, L. Tallstedt, M. Abraham-Nordling, T. Andersson, G. Berg, J. Calissendorff, B. Hallengren, P. Hedner, M. Lantz, E. Nystrom, et al. Thyroid-Associated Ophthalmopathy after Treatment for Graves' Hyperthyroidism with Antithyroid Drugs or Iodine-131 J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3700 - 3707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vannucchi, I. Campi, D. Covelli, D. Dazzi, N. Curro, S. Simonetta, R. Ratiglia, P. Beck-Peccoz, and M. Salvi Graves' Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3381 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sisson, M. J. Schipper, C. C. Nelson, J. E. Freitas, and B. R. Frueh Radioiodine Therapy and Graves' Ophthalmopathy J. Nucl. Med., June 1, 2008; 49(6): 923 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, and O. Torring TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study Eur. J. Endocrinol., January 1, 2008; 158(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, G. Baker, D. Janus, C. A. Paddon, D. Fuhrer, and M. Ludgate Biological Effects of Thyrotropin Receptor Activation on Human Orbital Preadipocytes Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5197 - 5203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Kim, L LaBree, L Levin, and S E Feldon The relation of Graves' ophthalmopathy to circulating thyroid hormone status Br J Ophthalmol, January 1, 2004; 88(1): 72 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Cooper Antithyroid Drugs in the Management of Patients with Graves' Disease: An Evidence-Based Approach to Therapeutic Controversies J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3474 - 3481. [Full Text] [PDF]
|
|
|
|
 |
|
 D. D Streetman and U. Khanderia Diagnosis and Treatment of Graves Disease Ann. Pharmacother., July 1, 2003; 37(7): 1100 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]
|
|
|
|
|
|
B. M Hosal, J. K Swanson, C. R Thompson, S. Kubota, K. Gunji, J. S Kennerdell, and J. R Wall Significance of serum antibodies reactive with flavoprotein subunit of succinate dehydrogenase in thyroid associated orbitopathy Br J Ophthalmol, May 1, 1999; 83(5): 605 - 608. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Bartalena, C. Marcocci, F. Bogazzi, L. Manetti, M. L. Tanda, E. Dell'Unto, G. Bruno-Bossio, M. Nardi, M. P. Bartolomei, A. Lepri, et al. Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy N. Engl. J. Med., January 8, 1998; 338(2): 73 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Wiersinga Preventing Graves' Ophthalmopathy N. Engl. J. Med., January 8, 1998; 338(2): 121 - 122. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
